In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The closing price of Tvardi Therapeutics Inc (NASDAQ: TVRD) was $7.0 for the day, up 4.63% from the previous closing price of $6.69. In other words, the price has increased by $4.63 from its previous closing price. On the day, 1.78 million shares were traded. TVRD stock price reached its highest trading level at $7.11 during the session, while it also had its lowest trading level at $6.1501.
Ratios:
Our analysis of TVRD’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.04 and its Current Ratio is at 4.04. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
On October 14, 2025, Barclays Downgraded its rating to Equal Weight which previously was Overweight but kept the price unchanged to $5.
On October 13, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $61.Barclays initiated its Overweight rating on October 13, 2025, with a $61 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 28 ’25 when Posner Christopher sold 583 shares for $4.75 per share. The transaction valued at 2,769 led to the insider holds 13,109 shares of the business.
Terrillion Scott sold 163 shares of TVRD for $776 on Feb 28 ’25. The SEC’Y; CHIEF COMPLIANCE & G.C. now owns 7,190 shares after completing the transaction at $4.76 per share. On Feb 04 ’25, another insider, Posner Christopher, who serves as the PRESIDENT AND CEO of the company, sold 372 shares for $4.72 each. As a result, the insider received 1,756 and left with 13,692 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TVRD now has a Market Capitalization of 65642032 and an Enterprise Value of 24902032. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.98 while its Price-to-Book (P/B) ratio in mrq is 1.99.
Stock Price History:
The Beta on a monthly basis for TVRD is 0.39, which has changed by -0.2662474 over the last 52 weeks, in comparison to a change of 0.13724327 over the same period for the S&P500. Over the past 52 weeks, TVRD has reached a high of $43.65, while it has fallen to a 52-week low of $5.65. The 50-Day Moving Average of the stock is -77.54%, while the 200-Day Moving Average is calculated to be -69.49%.
Shares Statistics:
TVRD traded an average of 140.98K shares per day over the past three months and 867230 shares per day over the past ten days. A total of 9.37M shares are outstanding, with a floating share count of 6.16M. Insiders hold about 34.31% of the company’s shares, while institutions hold 20.79% stake in the company. Shares short for TVRD as of 1759190400 were 675167 with a Short Ratio of 6.04, compared to 1756425600 on 680399.
Earnings Estimates
The stock of Tvardi Therapeutics Inc (TVRD) is currently in the spotlight, with 5 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.74, with high estimates of -$0.46 and low estimates of -$0.95.
Analysts are recommending an EPS of between -$1.92 and -$2.58 for the fiscal current year, implying an average EPS of -$2.23. EPS for the following year is -$2.53, with 5.0 analysts recommending between -$1.42 and -$5.71.
